Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

Author： Terret C.   Zanetta S.   Roche H.   Schellens J.H.M.   Faber M.N.   Wanders J.   Ravic M.   Droz J.P.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.39, Iss.8, 2003-05, pp. : 1097-1104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

By Awada A.   Thodtmann R.   Piccart M.J.   Wanders J.   Schrijvers A.H.G.J.   Von Broen I.-M.   Hanauske A.R.  

European Journal of Cancer, Vol. 39, Iss. 6, 2003-04 ,pp. : 742-747

Elsevier

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma

By Ueno Hideki   Okada Shuichi   Okusaka Takuji   Ikeda Masafumi   Kuriyama Hitoshi  

Cancer Chemotherapy and Pharmacology, Vol. 49, Iss. 2, 2002-02 ,pp. : 155-160

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Yondelis(TM) (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

By Twelves C.   Hoekman K.   Bowman A.   Vermorken J.B.   Anthoney A.   Smyth J.   van Kesteren C.   Beijnen J.H.   Uiters J.   Wanders J.   Gomez J.   Guzman C.   Jimeno J.   Hanauske A.   for the New Drug Development Group of the EORTC  

European Journal of Cancer, Vol. 39, Iss. 13, 2003-09 ,pp. : 1842-1851

Elsevier

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins v 3 and v 5 in patients with advanced solid tumours

By Eskens F.A.L.M.   Dumez H.   Hoekstra R.   Perschl A.   Brindley C.   Bottcher S.   Wynendaele W.   Drevs J.   Verweij J.   van Oosterom A.T.  

European Journal of Cancer, Vol. 39, Iss. 7, 2003-05 ,pp. : 917-926

Elsevier

Access to resources Recommend Favorite

An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

By Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 623-630

Springer Publishing Company

Access to resources Recommend Favorite